Antharis Therapeutics, Inc.
PrivateLast Round
Series A
Jul 14, 2022
Total Funding Raised
$48.2M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Antharis Therapeutics, Inc. is a biotechnology company that develops monoclonal antibodies and antibody-drug conjugates to treat cancer and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antharis Therapeutics, Inc. Comparables
Compare Antharis Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abalone Bio | 80% | |
| Elemental Biologics | 79% | |
| Catena Biosciences | 79% |
Antharis Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 14, 2022 | ||||
| Seed | Dec 1, 2020 |
Antharis Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yazbeck & Co. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 636% MoM.
- Jun 26, 2026
Grew 25% QoQ, from 16 to 20 employees.
Recent news
Latest coverage and updates
- is_developingJun 15, 2026
Antharis Therapeutics, Inc. is developing novel dual-payload ADCs targeting gastrointestinal cancers on Jun 15th '26.
Antharis Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Antharis Therapeutics, Inc.'s valuation, stock price, and market status.
Is Antharis Therapeutics, Inc. a public or private company?
Antharis Therapeutics, Inc. is a private company.
What is the current stock price of Antharis Therapeutics, Inc.?
Antharis Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Antharis Therapeutics, Inc. worth (valuation)?
Valuation information for Antharis Therapeutics, Inc. is not publicly available.
Can I buy Antharis Therapeutics, Inc. stock?
Antharis Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Antharis Therapeutics, Inc.'s last funding round?
Funding round information for Antharis Therapeutics, Inc. is not publicly available.
Who are the main investors in Antharis Therapeutics, Inc.?
Investor information for Antharis Therapeutics, Inc. is not publicly disclosed.
Will Antharis Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Antharis Therapeutics, Inc..
How can I track Antharis Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Antharis Therapeutics, Inc.'s secondary market activity and sign up for updates.